Since 1986 - Covering the Fastest Computers in the World and the People Who Run Them

Language Flags
May 11, 2011

The Genomics Conundrum

Michael Feldman

Over the last few years, biotech advocates have been preparing consumers with the idea of a $1,000 genome. At that price, a new era of personalized medicine will be at hand — or so says the conventional wisdom.

But the $1,000 genome just delivers the raw data of DNA base pairs. The analysis of that genome, that is, turning it into something useful, costs 10 times as much. That according to a recent article in Chemical & Engineering News (C&EN), which cited an article on the subject that appeared last fall in Genome Medicine.

The C&EN piece points out that while the price of genome sequencing has dropped dramatically, from close to a million dollars in 2007 to around a thousand dollars in 2010, the price of analysis has remained stubbornly high. And the reason? According to the article, it’s basically a question of data overload, for both the algorithms and computers that mine the data, as well as the scientists that have to direct the analysis:

[G]enomics analysis is a multidisciplinary function. In assessing one genome from a specific patient, data analysis needs to be performed by molecular and computational biologists, geneticists, pathologists, and physicians, all with different skill sets and requirements of the data.

One solution is to try to design the data collection with its end use in mind. According to Elaine Mardis, director of technology development at the Genome Institute at Washington University, the rationale is to reduce the amount of raw data, while making it more applicable to the clinical application — drug discovery, genomic testing, whatever. “You need to engineer data analysis so that you don’t generate a genome in eight to 10 days and then take four to five months to analyze it,” she told C&EN.

The bottom line is that genome sequencing is well on its way to becoming a commodity, while the analysis has yet to make that leap. Drug companies and other biotech firms are catching on to this new dynamic and are beginning to rethink their approaches.

Full story at Chemical & Engineering News

SC14 Virtual Booth Tours

AMD SC14 video AMD Virtual Booth Tour @ SC14
Click to Play Video
Cray SC14 video Cray Virtual Booth Tour @ SC14
Click to Play Video
Datasite SC14 video DataSite and RedLine @ SC14
Click to Play Video
HP SC14 video HP Virtual Booth Tour @ SC14
Click to Play Video
IBM DCS3860 and Elastic Storage @ SC14 video IBM DCS3860 and Elastic Storage @ SC14
Click to Play Video
IBM Flash Storage
@ SC14 video IBM Flash Storage @ SC14  
Click to Play Video
IBM Platform @ SC14 video IBM Platform @ SC14
Click to Play Video
IBM Power Big Data SC14 video IBM Power Big Data @ SC14
Click to Play Video
Intel SC14 video Intel Virtual Booth Tour @ SC14
Click to Play Video
Lenovo SC14 video Lenovo Virtual Booth Tour @ SC14
Click to Play Video
Mellanox SC14 video Mellanox Virtual Booth Tour @ SC14
Click to Play Video
Panasas SC14 video Panasas Virtual Booth Tour @ SC14
Click to Play Video
Quanta SC14 video Quanta Virtual Booth Tour @ SC14
Click to Play Video
Seagate SC14 video Seagate Virtual Booth Tour @ SC14
Click to Play Video
Supermicro SC14 video Supermicro Virtual Booth Tour @ SC14
Click to Play Video